Dr Phil Jeffrey
Phil Jeffrey Ph.D. is an independent consultant with over 35 years’ experience in the pharmaceutical industry and a successful track record in drug discovery from early lead optimisation through to clinical proof of mechanism and proof of concept. He has worked across a wide variety of therapeutic areas including; auto-immunity, inflammation, CNS, anti-infectives, epigenetics, cardiovascular and most recently rare diseases at Pfizer, where he was responsible for developing translational science strategies across all stages of the portfolio.
Prior to joining Pfizer, Phil worked at GlaxoSmithKline (GSK) and in addition to leading the Quantitative Pharmacology and Translational Sciences group he was instrumental in developing approaches to preclinical pk/pd modelling and simulation, early human clinical dose predictions and understanding drug disposition in the CNS. Before joining GSK, Phil worked at SmithKlineBeecham and The Upjohn Company leading and supporting early phase drug discovery projects for both US and UK research programmes.
Phil has a PhD in pharmacokinetics and drug metabolism from the University of Sheffield and is an Honorary Professor at the William Harvey Research Institute, Queen Mary University of London. He is a member of the editorial board for the British Journal of Pharmacology and Xenobiotica and has authored/co-authored over 50 peer reviewed papers and 4 book chapters.